• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组织型纤溶酶原激活物/神经丝氨酸蛋白酶抑制剂轴在阿尔茨海默病中的可能作用:新视角。

The probable role of tissue plasminogen activator/neuroserpin axis in Alzheimer's disease: a new perspective.

机构信息

Department of Internal Medicine, Medical College, Najran University, Najran, Saudi Arabia.

Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustansiriyia University, PO Box 14132, Baghdad, Iraq.

出版信息

Acta Neurol Belg. 2024 Apr;124(2):377-388. doi: 10.1007/s13760-023-02403-x. Epub 2023 Nov 2.

DOI:10.1007/s13760-023-02403-x
PMID:37917293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10965687/
Abstract

Alzheimer's disease (AD) is the most common type of dementia associated with amyloid beta (Aβ) deposition. Dysfunction of the neuronal clearance pathway promotes the accumulation of Aβ. The plasminogen-activating system (PAS) is controlled by various enzymes like tissue plasminogen activators (tPA). Neuronal tPA enhances the conversion of plasminogen to plasmin, which cleaves Aβ; this function is controlled by many inhibitors of PAS, including a plasminogen-activating inhibitor (PAI-1) and neuroserpin. Therefore, the objective of the present narrative review was to explore the potential role of tPA/neuroserpin in the pathogenesis of AD. PAI-1 activity is increased in AD, which is involved in accumulating Aβ. Progressive increase of Aβ level during AD neuropathology is correlated with the over-production of PAI-1 with subsequent reduction of plasmin and tPA activities. Reducing plasmin and tPA activities promote Aβ by reducing Aβ clearance. Neuroserpin plays a critical role in the pathogenesis of AD as it regulates the expression and accumulation of Aβ. Higher expression of neuroserpin inhibits the neuroprotective tPA and the generation of plasmin with subsequent reduction in the clearance of Aβ. These observations raise conflicting evidence on whether neuroserpin is neuroprotective or involved in AD progression. Thus, neuroserpin over-expression with subsequent reduction of tPA may propagate AD neuropathology.

摘要

阿尔茨海默病(AD)是最常见的与淀粉样蛋白β(Aβ)沉积相关的痴呆症。神经元清除途径的功能障碍促进了 Aβ的积累。纤溶酶原激活系统(PAS)受各种酶如组织型纤溶酶原激活物(tPA)的控制。神经元型 tPA 增强纤溶酶原向纤溶酶的转化,从而切割 Aβ;这一功能受许多 PAS 抑制剂的控制,包括纤溶酶原激活抑制剂(PAI-1)和神经丝氨酸蛋白酶抑制剂(neuroserpin)。因此,本综述的目的是探讨 tPA/neuroserpin 在 AD 发病机制中的潜在作用。AD 中 PAI-1 活性增加,这与 Aβ的积累有关。AD 神经病理学过程中 Aβ水平的逐渐增加与 PAI-1 的过度产生相关,随后导致纤溶酶和 tPA 活性降低。降低纤溶酶和 tPA 活性会通过减少 Aβ清除来促进 Aβ的积累。神经丝氨酸蛋白酶抑制剂在 AD 的发病机制中起着关键作用,因为它调节 Aβ的表达和积累。神经丝氨酸蛋白酶抑制剂表达增加会抑制具有神经保护作用的 tPA 和纤溶酶的产生,随后导致 Aβ的清除减少。这些观察结果对神经丝氨酸蛋白酶抑制剂是否具有神经保护作用或是否参与 AD 进展提出了相互矛盾的证据。因此,tPA 表达减少伴随着神经丝氨酸蛋白酶抑制剂的过度表达可能会促进 AD 神经病理学的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/0e6168c02b56/13760_2023_2403_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/1ea40835f887/13760_2023_2403_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/cab655b64ffc/13760_2023_2403_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/f4a48dd6fa46/13760_2023_2403_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/19f9a70828a0/13760_2023_2403_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/cbb4c4605253/13760_2023_2403_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/0e6168c02b56/13760_2023_2403_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/1ea40835f887/13760_2023_2403_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/cab655b64ffc/13760_2023_2403_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/f4a48dd6fa46/13760_2023_2403_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/19f9a70828a0/13760_2023_2403_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/cbb4c4605253/13760_2023_2403_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f41/10965687/0e6168c02b56/13760_2023_2403_Fig6_HTML.jpg

相似文献

1
The probable role of tissue plasminogen activator/neuroserpin axis in Alzheimer's disease: a new perspective.组织型纤溶酶原激活物/神经丝氨酸蛋白酶抑制剂轴在阿尔茨海默病中的可能作用:新视角。
Acta Neurol Belg. 2024 Apr;124(2):377-388. doi: 10.1007/s13760-023-02403-x. Epub 2023 Nov 2.
2
Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.衰老和淀粉样β蛋白沉积对阿尔茨海默病Tg2576小鼠模型中纤溶酶原激活剂和纤溶酶原激活剂抑制剂-1的影响。
Brain Res. 2015 Feb 9;1597:159-67. doi: 10.1016/j.brainres.2014.11.042. Epub 2014 Nov 29.
3
Activators and inhibitors of the plasminogen system in Alzheimer's disease.阿尔茨海默病中纤溶酶原系统的激活剂和抑制剂。
J Cell Mol Med. 2012 Apr;16(4):865-76. doi: 10.1111/j.1582-4934.2011.01394.x.
4
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.在一种新型神经丝氨酸蛋白酶抑制剂缺乏型阿尔茨海默病转基因小鼠模型中,淀粉样β水平显著降低,空间记忆缺陷得到挽救。
J Neurochem. 2011 Sep;118(5):928-38. doi: 10.1111/j.1471-4159.2011.07359.x. Epub 2011 Jul 18.
5
The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration.组织型纤溶酶原激活剂 - 纤溶酶原蛋白水解级联反应可加速β淀粉样蛋白(Aβ)的降解并抑制Aβ诱导的神经退行性变。
J Neurosci. 2003 Oct 1;23(26):8867-71. doi: 10.1523/JNEUROSCI.23-26-08867.2003.
6
The plasminogen activating system in the pathogenesis of Alzheimer's disease.纤溶酶原激活系统在阿尔茨海默病发病机制中的作用
Neural Regen Res. 2021 Oct;16(10):1973-1977. doi: 10.4103/1673-5374.308076.
7
Plasmin system of Alzheimer's disease patients: CSF analysis.阿尔茨海默病患者的纤溶系统:脑脊液分析。
J Neural Transm (Vienna). 2012 Jul;119(7):763-9. doi: 10.1007/s00702-012-0778-y. Epub 2012 Mar 14.
8
Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.通过维持纤溶酶蛋白水解级联反应增强大脑中β淀粉样蛋白的清除。
Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8754-9. doi: 10.1073/pnas.0710823105. Epub 2008 Jun 16.
9
A Small Molecule Inhibitor of Plasminogen Activator Inhibitor-1 Reduces Brain Amyloid-β Load and Improves Memory in an Animal Model of Alzheimer's Disease.一种纤溶酶原激活物抑制剂-1 的小分子抑制剂可降低阿尔茨海默病动物模型的脑内淀粉样β负荷并改善记忆。
J Alzheimers Dis. 2018;64(2):447-457. doi: 10.3233/JAD-180241.
10
Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition.组织型纤溶酶原激活剂需要纤溶酶原调节β淀粉样蛋白的神经毒性和沉积。
J Neurochem. 2000 Nov;75(5):2172-7. doi: 10.1046/j.1471-4159.2000.0752172.x.

引用本文的文献

1
Unlocking Alzheimer's Disease: The Role of BDNF Signaling in Neuropathology and Treatment.揭开阿尔茨海默病之谜:脑源性神经营养因子信号传导在神经病理学及治疗中的作用
Neuromolecular Med. 2025 May 17;27(1):36. doi: 10.1007/s12017-025-08857-x.
2
The Conceivable Role of Metabolic Syndrome in the Pathogenesis of Alzheimer's Disease: Cellular and Subcellular Alterations in Underpinning a Tale of Two.代谢综合征在阿尔茨海默病发病机制中可能扮演的角色:支撑“双故事”的细胞及亚细胞改变
Neuromolecular Med. 2025 May 16;27(1):35. doi: 10.1007/s12017-025-08832-6.
3
Internet of Medical Things (IoMT) for Alzheimer Patient's Outcome.

本文引用的文献

1
Enhancement of neural regeneration as a therapeutic strategy for Alzheimer's disease (Review).增强神经再生作为阿尔茨海默病的一种治疗策略(综述)。
Exp Ther Med. 2023 Aug 1;26(3):444. doi: 10.3892/etm.2023.12143. eCollection 2023 Sep.
2
Primary Hypothyroidism and Alzheimer's Disease: A Tale of Two.原发性甲状腺功能减退症与阿尔茨海默病:二者的关系
Cell Mol Neurobiol. 2023 Oct;43(7):3405-3416. doi: 10.1007/s10571-023-01392-y. Epub 2023 Aug 4.
3
Targeting mitophagy for neurological disorders treatment: advances in drugs and non-drug approaches.
用于阿尔茨海默病患者治疗效果的医疗物联网(IoMT)
CNS Neurol Disord Drug Targets. 2025;24(7):491-493. doi: 10.2174/0118715273371149250218081425.
4
Amyloid-β and heart failure in Alzheimer's disease: the new vistas.阿尔茨海默病中的β-淀粉样蛋白与心力衰竭:新视野
Front Med (Lausanne). 2025 Feb 4;12:1494101. doi: 10.3389/fmed.2025.1494101. eCollection 2025.
5
Alterations in the Processing of Platelet APP (Amyloid Beta Precursor Protein) in Alzheimer Disease: The Possible Nexus.阿尔茨海默病中血小板淀粉样前体蛋白(APP)加工过程的改变:可能的联系
Neuropsychopharmacol Rep. 2025 Mar;45(1):e12525. doi: 10.1002/npr2.12525.
6
The Aggravating Role of Failing Neuropeptide Networks in the Development of Sporadic Alzheimer's Disease.功能失调的神经肽网络在散发性阿尔茨海默病发生发展中的加重作用
Int J Mol Sci. 2024 Dec 5;25(23):13086. doi: 10.3390/ijms252313086.
7
Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon.低血糖与阿尔茨海默病风险:地特胰岛素的可能作用。
Cell Mol Neurobiol. 2024 Jul 8;44(1):55. doi: 10.1007/s10571-024-01489-y.
8
BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy.BDNF/TrkB 激活剂在帕金森病中的作用:一种新的治疗策略。
J Cell Mol Med. 2024 May;28(10):e18368. doi: 10.1111/jcmm.18368.
9
Quantitative Proteomics Reveal Region-Specific Alterations in Neuroserpin-Deficient Mouse Brain and Retina: Insights into Serpini1 Function.定量蛋白质组学揭示神经丝氨酸蛋白酶缺陷型小鼠脑和视网膜中的区域特异性改变:对Serpini1功能的深入了解。
Proteomes. 2024 Mar 14;12(1):7. doi: 10.3390/proteomes12010007.
10
Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue.糖原合酶激酶 3β(GSK-3β)抑制剂在帕金森病中的治疗潜力:探索被忽视的途径。
Mol Neurobiol. 2024 Sep;61(9):7092-7108. doi: 10.1007/s12035-024-04003-z. Epub 2024 Feb 17.
针对线粒体自噬治疗神经疾病:药物及非药物方法的进展
Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec;396(12):3503-3528. doi: 10.1007/s00210-023-02636-w. Epub 2023 Aug 3.
4
Impact of apolipoprotein E isoforms on sporadic Alzheimer's disease: beyond the role of amyloid beta.载脂蛋白E亚型对散发性阿尔茨海默病的影响:超越β淀粉样蛋白的作用
Neural Regen Res. 2024 Jan;19(1):80-83. doi: 10.4103/1673-5374.375316.
5
The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS).磷酸二酯酶 5 抑制剂在急性缺血性脑卒中(AIS)中的潜在治疗效果。
Mol Cell Biochem. 2024 May;479(5):1267-1278. doi: 10.1007/s11010-023-04793-1. Epub 2023 Jul 3.
6
Insomnia Impairs Both the Pro-BDNF and the BDNF Levels Similarly to Older Adults with Cognitive Decline: An Exploratory Study.失眠同样会降低认知能力下降的老年人的 pro-BDNF 和 BDNF 水平:一项探索性研究。
Int J Mol Sci. 2023 Apr 17;24(8):7387. doi: 10.3390/ijms24087387.
7
The Breakthroughs and Caveats of Using Human Pluripotent Stem Cells in Modeling Alzheimer's Disease.利用人类多能干细胞在阿尔茨海默病建模中的突破与局限性。
Cells. 2023 Jan 27;12(3):420. doi: 10.3390/cells12030420.
8
Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1).纤溶酶原激活物抑制剂 1(PAI-1)的过去、现在和未来展望。
Semin Thromb Hemost. 2023 Apr;49(3):305-313. doi: 10.1055/s-0042-1758791. Epub 2022 Dec 15.
9
Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review.他汀类药物在阿尔茨海默病中的应用:疯狂探索与叙述性综述的祸还是福
Brain Sci. 2022 Sep 24;12(10):1290. doi: 10.3390/brainsci12101290.
10
Brain-derived neurotrophic factor in main neurodegenerative diseases.主要神经退行性疾病中的脑源性神经营养因子
Neural Regen Res. 2023 Mar;18(3):554-555. doi: 10.4103/1673-5374.350199.